Dose Insider / Outsourcing pharmacies / ProRx LLC

ProRx LLCFDA registration and inspection record

FDA list of November 17, 2026 · checked against fda.gov on November 20, 2026

ProRx LLC in Exton, Pennsylvania is registered with FDA as a 503B outsourcing facility, first on April 27, 2022 and most recently on February 20, 2026. FDA last inspected it on November 10, 2026 and issued a Form 483.

Inspected 2026last FDA inspection November 10, 2026
Facilities registered, by first yearFDA list of November 17, 2026; this facility’s year in coral2019620203202112022, this one420239202415202514202614Facilities registered, byfirst yearFDA list of November 17, 2026; this facility’syear in coral2019620203202112022, this one420239202415202514202614

From FDA’s list of registered outsourcing facilities, November 17, 2026.

On this page

These facts come from FDA’s list of registered outsourcing facilities, updated November 17, 2026, and from the inspection report FDA posted with it.1 FDA’s warning letters about GLP-1 drugs name this company 2 times; they are listed below.

What does FDA’s record show, in brief?

FacilityProRx LLC
LocationExton, Pennsylvania
Type503B outsourcing facility
Registered sinceApril 27, 2022
Latest registrationFebruary 20, 2026
Last FDA inspectionNovember 10, 2026
Inspection dates—
Form 483Issued
FDA action after the inspectionOpen
Compounds sterile drugs from bulkYes
FDA warning letters on GLP-1 drugs2

Has this facility recalled any drugs?

FDA’s enforcement reports list 14 recalled products from this facility, from August 22, 2024 to October 15, 2025: 14 in Class II. 14 of them name a GLP-1 drug. Class I is the most serious: FDA uses it when the product could cause serious harm.3

StartedClassProductReason
2025-10-15IISemaglutide InjectionLack of Assurance of Sterility
2025-10-15IISemaglutide InjectionLack of Assurance of Sterility
2025-10-15IISemaglutide InjectionLack of Assurance of Sterility
2025-10-15IISemaglutide InjectionLack of Assurance of Sterility
2025-10-15IITirzepatide InjectionLack of Assurance of Sterility
2025-10-15IISemaglutide InjectionLack of Assurance of Sterility
2025-10-15IISemaglutide InjectionLack of Assurance of Sterility
2024-08-22IITirzepatide 2 mL (10 mg/mL) and 20 mg/mLLack of Assurance of Sterility

The table shows 8 of the 14 recalls, those naming a GLP-1 drug first; the rest are in FDA’s enforcement reports.

Which FDA warning letters name this company?

Is the pharmacy behind my prescription on FDA’s list?

Type a pharmacy name or city. The search runs over all 100 facilities on FDA’s list; a 503A pharmacy that compounds for individual prescriptions is licensed by its state and is not on this list.

Pharmacy check100 facilities
Registered 503B—
With a Form 483—

Where are the registered outsourcing facilities?

6 of the 100 facilities on FDA’s list are in Pennsylvania. The chart counts them by state; choose a view to see which ones FDA has inspected.

Facilities by stateFDA list, November 17, 2026
Show
Facilities—
Top state—

Which other facilities are in the same state?

What does it mean that a pharmacy is a 503B outsourcing facility?

An outsourcing facility is a compounder that has chosen to register with FDA under section 503B of the Federal Food, Drug, and Cosmetic Act. It must re-register every year between October 1 and December 31 and pay an annual fee; a facility that does not is removed from FDA’s list on January 1.1 Once registered, it joins the list of facilities FDA plans to inspect on a risk-based schedule.1

A Form FDA 483 lists what investigators observed during an inspection. FDA states that a 483 is issued when investigators see significant objectionable conditions, and that it is not a final agency determination that the law was broken.1 Registration is not FDA approval of the drugs a facility makes: compounded drugs are not FDA-approved.

Sources

  1. FDA. Facilities registered as human drug compounding outsourcing facilities under section 503B, updated November 17, 2026, with its notes on registration and inspections. fda.gov
  2. FDA. Registered outsourcing facilities: inspection status of ProRx LLC. fda.gov
  3. FDA. Drug recall enforcement reports for ProRx LLC, read through openFDA on November 20, 2026. open.fda.gov

Log every dose in mg with the vial it came from, so there is a record if something goes wrong.

Open Dose Insider